Good morning. My name is Julie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Cascades first quarter 2023 financial results conference call. All lines are currently in a listen-only mode. After the speaker's remarks, there will be a question-and-answer session. I will now pass the call over to Jennifer Aitken, Director of Investor Relations for Cascades. Ms. Aitken, you may begin your conference.
Thank you, operator. Good morning, everyone, and thank you for joining our first quarter 2023 conference call. We will begin with an overview of our operational and financial results, followed by some concluding remarks and highlights of our 2022- 2024 strategic plan update that was released this morning. After which we will begin the question period. Today's speakers will be Mario Plourde, President and CEO, and Allan Hogg, CFO. Also joining us for the question period at the end of the call are Charles Malo, President and COO of Containerboard Packaging, Luc Langevin, President and COO of Specialty Products, and Jean-David Tardif, President and COO of Tissue Papers. Before I turn the call over to my colleagues, I would like to highlight that certain statements made during this call will discuss historical and forward-looking matters.
The accuracy of these statements is subject to risk factors that can have a material impact on actual results. These risks are listed in our public filings. These statements, the investor presentation, and the press release also include data that are not measures of performance under IFRS. Please refer to our Q1 2023 investor presentation for details. This presentation, along with our first quarter press release, can be found in the investor section of our website. The company's 2022-2024 strategic plan update document can also be found on our website and on SEDAR later today. If you have any questions, please feel free to contact us after the session. I will now turn the call over to our CEO. Mario?
Thank you, Jennifer. Good morning, everyone. Before discussing our first quarter results, I would like to mention that we published our updated 2022-2024 strategic plan this morning. I will briefly discuss some of the highlights at the end of this call. This document is available on SEDAR and on our website. Moving now to our first quarter result. We are pleased with our Q1 consolidated performance. First quarter sales increased 9% year-over-year, while adjusted EBITDA of CAD 134 million more than doubled from last year. In both cases, selling prices and foreign exchange were beneficial, while volume and sales mix had a net negative impact. Lower raw material cost was a tailwind at the EBITDA level, offsetting the impact of higher production costs year-over-year.
Sequentially, sales were stable as negative impact from pricing, sales mix and foreign exchange fully offset the benefit of stronger volume in all business segments. EBITDA increased CAD 80 million or 16% sequentially. This was driven by a raw material pricing tailwind, favorable volume and mix in our packaging segments, and stronger results from our Tissue segment. On the raw material side, highlighted on slide six and seven, the Q1 average index price for OCC decreased 76% year-over-year and 6% from Q4. The OCC market was relatively balanced in the first quarter, with limited export activity counterbalancing the lower seasonal generation. Index prices saw a marginal correction recently to a more normalized level, remain at historic lows. We are not expecting any material pricing movement in the short term, giving the slow export levels and higher seasonal generation.
Average index prices for white recycled paper grades decreased 11% in Q1, but remained 8% above the prior year levels. We saw more favorable market dynamics over the quarter and more recently. Similar trends were seen with virgin pulp. The hardwood pulp index decreased 5% sequentially, but was 16% higher year-over-year, while softwood pulp index prices decreased 4% from Q4 and were up 10% year-over-year. Conditions have improved for virgin pulp following lower demand from Asia, improved logistics, and steadier domestic production and new capacity. Pricing indexes have been going down rapidly recently, which will provide some cost relief in our Tissue segment. Material is available and our mills are adequately supplied. Moving now to the result of each of our business segments, as highlighted on page 8 through 13 of the presentation.
Beginning with the sequential performance, sales in Containerboard decreased 1% in Q1. This was driven by a less favorable mix and lower USD selling prices for both parent rolls and converted products. The 5% volume increase reflects a 16% increase in shipment of parent roll and a 4% decrease in converted product shipments. Sequentially, converting shipments decreased by 3% in Canada, underperforming the 0.5% increase in the Canadian market. U.S. converting shipment decreased 8.4% below the 1% U.S. market decrease. I would highlight that Cascades outperformed both the Canadian and the U.S. market in the previous quarter, impacting sequential relative performance in the current quarter. Q1 adjusted EBITDA of CAD 126 million or 22.5% on a margin basis, was 6% above the Q4 levels.
Q1 results include the final CAD 7 million insurance settlement from water effluent treatment issue in mid-2021 at our Niagara Falls complex, while those of Q4 include the first CAD 5 million partial settlement related to this claim. Sequentially, EBITDA level benefited from higher volume and lower raw material, energy, and production costs. These were partially offset by lower U.S. selling prices and a less favorable sales mix. Year-over-year sales increased by 5%, driven by pricing, volume, and foreign exchange. EBITDA increased by 58% or CAD 46 million, reflecting lower raw material costs, more favorable exchange rate, and a slight selling price benefit. Year-over-year shipment increased by 3%, reflecting a 10% increase in external parent rolls, offset by a 4% decrease in converting shipments, mainly driven by lower volume in the Canadian market.
Continuing with our packaging business, Q1 sales levels in our Specialty Products segment were stable sequentially. This reflected slightly higher volume in our cardboard and molded pulp segment and higher average selling price in our plastic activities, offset by a less favorable mix and lower average selling price, primarily in cardboard. EBITDA increased by CAD 7 million sequentially, reflecting better realized spread in most of our segments, higher volume, and lower transportation costs. These were partially offset by higher operational costs during the quarter. When compared to the prior year, Q1 sales increased by CAD 4 million or 3%, driven by higher average selling prices and a more favorable exchange rate. EBITDA level increased 23% or CAD 5 million as higher realized spread and a more favorable exchange rate, more than offset the lower volume in plastic and cardboard and higher transportation and production costs.
Moving now to Tissue business. Sales were stable sequentially in Q1, while adjusted EBITDA levels doubled to CAD 16 million. Top- line performance reflect higher selling prices and slightly stronger volume, as well as ongoing profitability and productivity initiatives, partially offset by a less favorable mix. Shipments increased 1% from Q4, reflecting a 3% decrease in shipment of converted product and a 27% increase in parent roll shipments following the restart of our machine at the St. Helens facility in February. Sequentially, EBITDA improve was largely driven by benefit from improved selling prices and lower raw material prices. Year-over-year, sales levels rose 23%, with pricing and sales mix initiatives and more favorable exchange rate offsetting the impact of lower volume. Q1 EBITDA of CAD 16 million compared to a loss of CAD 17 million in the prior- year period.
This year-over-year improvement was driven by higher selling prices and lower transportation costs, the benefit of which more than offset higher raw material, labor, and production costs. Allan will now discuss the main highlight of our financial performance, after which I will discuss the highlight of our updated 2022-2024 strategic plan and conclude our presentation. Allan?
Yes. Thank you, Mario. Good morning, everyone. Slides 14 and 15 illustrate the specific items recorded during the quarter. The main items that impacted EBITDA were CAD 152 million of impairment charges in our Tissue and Containerboard segments related to U.S. assets. In addition, net earnings also include a CAD 9 million gain on the sale of an investment in a joint venture in our Tissue segment. Slides 16 and 17 illustrate the year-over-year and sequential variance of our Q1 adjusted earnings per share and the reconciliation with the specific items that affected our quarterly results. As reported, Q1 net loss per share was CAD 0.75. This compared to a net loss per share of CAD 0.15 last year and a net loss of CAD 0.27 per share in Q4 2022. On an adjusted basis, net earnings per share were CAD 0.32 in the current quarter.
This compared to a net loss per share of CAD 0.15 in last year's results and net earnings per share of CAD 0.22 in Q4. In both periods, this variance mainly reflects improved adjusted EBITDA. As highlighted on slide 18, first quarter adjusted cash flow from operations increased by CAD 64 million year-over-year to CAD 90 million, and adjusted cash flow levels improved by CAD 22 million year-over-year. This reflects higher operating results and significantly higher interest and net CapEx paid in the current period, largely associated with our Bear Island project. Slide 19 provides details about our capital investments. Paid CapEx, net of disposal totaled CAD 137 million in Q1. Of this amount, CAD 100 million was paid for the Bear Island project. For 2023, our planned capital investments of CAD 325 million, which includes approximately CAD 175 million for Bear Island, have not changed.
Moving now to our net debt reconciliation. Our net debt increased by CAD 104 million in the first quarter. This is a reflection of the combined effects of our current investment in Bear Island and usual working capital requirements exceeding cash flow from operating activities. Our leverage ratio of 4.6x is down from 5.2x at the end of Q4. As we have mentioned in the past, we expect this leverage trend to continue with improved operational performance of our Tissue segment and the start-up of operations at the Bear Island facility. When excluding cash investment made to date in Bear Island and its negative contribution to operating results, our leverage ratio would stand at approximately 3.1x . Financial ratios and information about maturities are detailed on slide 21.
Sequential and year-over-year sales and EBITDA performance analysis can be found on slide 38 through 41 of the deck. Cost of sales detail on slide 42, and historical index pricing on slide 43 and 44. Mario will now conclude the call with some brief comments and an update on our strategic plan before we begin the question period. Mario?
Thank you, Allan. We provide details regarding our near-term outlook on slide 22 of the presentation. As a reminder, this outlook is based on what we are seeing currently and may change in the coming weeks. Our near-term outlook for Containerboard is for result to be lower sequentially. This is driven by slightly higher raw material costs, lower average selling prices, slightly softer volume, and reflect the recent start-up of the Bear Island and non-recurrent of the Q1 insurance income. We are expecting slightly softer results sequentially from the Specialty Products segment. This reflects stable volume and selling prices trend offset by slightly higher raw material costs. Our outlook for Tissue is for a second quarter result to improve sequentially and to be significantly above prior- year levels. This stronger outlook reflect more favorable raw material prices, ongoing initiatives, and stable volume.
Moving now to our updated 2022-2024 strategic plan. We provide highlight on slide 24- 36 in the presentation and invite you to refer to our detailed strategic plan update document that is available on our website and SEDAR. Before going into some of the details, I would like to underscore that our focus remains squarely on driven revenue, profitability level, and efficiency across our business platform. To this end, our 2024 objective remain largely unchanged. What has changed, most notably for our Tissue business, is the path we are taking to get there. At the operation level, our updated plan takes into account the changes to our Tissue platform, the revised ramp-up schedule of our Bear Island mills, and the closure of one of our containerboard machines at our Niagara Falls facility.
We have also refreshed growth target for some of our strategic market to reflect demand trends and fine-tuning of our commercial approach and have updated pricing and input cost parameter to reflect current market conditions. With that, I will start with our Containerboard business. We are very pleased to have announced that the first paper rolls was produced at the Bear Island facility on May second. We have updated annual production and EBITDA forecast for 2023 to account for this start-up. Our 2024 and 2025 and full potential forecasts have also been updated to reflect current market conditions. Notwithstanding the higher project cost and the delay in start-up following the significant inflationary cost pressure and supply chain disruption in 2021 and 2022, this facility remained a key strategic move for our Containerboard business.
Lightweight, 100% recycled, and geographically well-positioned, the mill position in our Containerboard operation platform very competitively from our customers' perspective and in term of our ability to provide customer with top quality, low basis weight recycled solution. We provide the highlights of our updated action plan for Containerboard on slide 27 and 28. At the revenue level, our 2024 target has decreased to CAD 2.6 billion from CAD 2.9 billion, and our EBITDA margin target decreased slightly to a range of 18%-20% from 19%-21%. These reflect updated margin prices and input cost assumption, including raw materials, and our decision to delay any potential decision on adding converting capacity. We will continue to explore opportunity in this regard, but our capital allocation focus right now is on debt repayment. Moving now to our Specialty Packaging segment.
This business performed well in 2022, generating sales growth of between 10% and 23% in each of its strategic market. Our objective for each of these market has been adjusted to account for changes in external demand pattern, realign our commercial strategy and priorities, capital allocation plan, and updated made to selling prices, raw material, and other production costs to reflect the current condition. As highlighted on slide 30, this business is on track to deliver on its 2024 objective. Two new sustainable product were successfully launched in 2022. A 100% recycled PET tray for the food processor and food retailer market, and the addition of innovative northbox XTEND technology to its line of isothermal packaging solution. Both are made of recycled material and are recyclable. In addition, six new product launches are planned for 2023.
In terms of financial performance, the 2024 revenue objective has been increased to approximately CAD 735 million from CAD 700 million. We continue to expect margin within the range of 17%-19%. We are very pleased with the growth and the potential we see in this business. It plays a central role of our goal to be the go-to provider for sustainable packaging solution for our customer. Turning now to our Tissue business. Before discussing our updated objective, I would like to take this opportunity to discuss the fact that led to our decision to reposition the operational platform of this business. As many of you know, we launched a comprehensive profitability plan for Tissue business in February 2022. The pandemic and the repercussion of recent geopolitical events led to significant turbulence and had a wide-ranging impacts on business.
Demand levels fluctuate widely, raw material costs rose dramatically, production and other input costs significantly increased, and the labor market became very constrained. The result generated by this business in 2022 are a testament to these factor as well as our own internal production challenge. Given this situation, change were necessary if we were to reach our goal. To do so, we conduct an extensive internal analysis and review the plan and initiative that had initially been set in February 2022. The repositioning announced at the end of April is the result of this analysis, which indicate that additional action were required to meet profitability and efficiency objective. In other word, our goal for this business remains largely the same is the path that we are taking to reach them that has changed. We provide an update overview of our operational base on slide 31.
With the changes to our Tissue platform, annual production capacity decreased by 92,000 short tons or 15% on the manufacturing side and by 10 million cases in converting. Slide 32 provide an update 2024 objective for this business following the announced change to our operational platform and amended market condition assumption. We will be focused on maximizing the operational efficiency and production capacity of our core production facilities while limiting investment to approximately CAD 35 million annually through 2024. A large part of our focus is on our U.S. operation, most notably the Oklahoma facility, where we have made good progress to the addition of management and technical resources focused on increasing production efficiency levels and improving overall execution.
The announced change to our platform and update made to our market condition assumption reduce our 2024 revenue objective to approximately CAD 1.5 billion, down from CAD 1.7 billion previously. Our 2024 EBITDA objective is now a range of CAD 120 million-CAD 140 million or 8%-9% on a margin basis. We walk you through the key factor driving these objectives on slide 33. I would highlight that the two main components supporting this objective are internally driven and are already in place. We will continue to explore additional initiatives to further improve profitability in our Tissue Group. As highlighted on slide 34, the adjustment to our 2024 Tissue objective and those of our packaging businesses result in only slight modification to consolidated objective.
Our 2024 revenue target remain unchanged to approximately CAD 5 billion. Our EBITDA margin target has slightly decreased to a range of 12%-14% from 13%-15% previously. Target free cash flow from levels are largely unchanged as well and are expected to reach 9%-10% on the revenue in 2024. We have slightly modified our 2024 year-end leverage target to a range of 2.5x-3x following lower levels of cash flow generation in 2022 due to the significant cost inflation and the higher Bear Island project costs. Our capital allocation priority are focused on reaching these leverage objectives and ultimately our goal of 2%-2.5% in the future. Given this, we are maintaining our dividend. We have not renewed our normal course issuer bid in 2023.
Our capital investment targets remain unchanged and will be limited to 4% of revenue for both 2023 and 2024, including the CAD 175 million for Bear Island in the current year. As I mentioned, we are focused on debt reduction and reaching our leverage objective. We provide an overview of how we currently see our net debt evolving over the 2022-2024 time frame on slide 35. Slide 36 summarize our top priority. We are focused on achieving our profitability objective in our Tissue Paper business and on ramping up production at our Bear Island mills. Over the long term, we will continue to explore opportunity to grow our sustainable packaging business in the U.S., including expansion our converting capacity. Let me be clear, however, that this is a long-term objective.
Our focus through the end of 2024 is on reaching our leverage target by limiting CapEx, reducing debt, and achieving our profitability target in each of our business segments. Overarching all these priority is our comprehensive sustainability action plan and our continuing goal to recruit the best talent and train and develop our most important asset, our employee. With that, we can now open the call for question. Operator?
Thank you. If you'd like to ask a question, simply press star, then the number one on your telephone keypad. If you'd like to withdraw your question, please press star two. Again, if you have a question, please press star then one on your telephone keypad. We'll pause for just a moment to compile the Q&A roster. Your first question comes from Matthew McKellar from RBC Capital Markets. Please go ahead.
Matthew?
Hi. Sorry about that. Thanks. Good morning. I think there's a comment that your Containerboard outlook for Q2 reflects slightly softer volume sequentially. I was wondering if you could provide just a bit of color on what trends you've seen in that business through April and the start of May, and how you're thinking about business, and its progression through the balance of the quarter.
Okay. Matthew, this is Charles. What we see now is the usual pickup in seasonal pickup is not as strong as expected. Though we see that the volume now are more in line with the pre-COVID, I would say. We're being cautious considering the question about the economy. That's why we when we see at our volume right now, we do are benefiting those from the growth from our investments that we made in Piscataway in New Jersey and also in Ontario. We're being cautious about our numbers, but we're also seeing at the same time that we do have some potential gain on the volume.
Okay, thanks. Moving over to the Tissue business, I think there's a comment that labor constraints there have improved. You've highlighted your efforts to attract, retain, develop talent as part of the strategic plan updates. I was wondering if you could provide a bit more clarity around whether labor is still a constraint on production at this point, what you might be hoping to achieve with your efforts there, whether it's from production perspective or metrics around turnover and retention. It also looks like you're maybe expecting more of your capacity to be unused in 2024 versus your prior expectations. I was wondering if that's maybe tied to the labor kind of issues there, if there are other drivers to be aware of. Thanks.
Good morning, Matthew. Jean-David. The constraint level is less than it was before, less than last year, for example. Our positions are filled, it's not a matter of recruiting anymore. We've been through this. Now it's a matter of training, getting the right level of skills and the right experience level to extract the most of the equipment. Yes, there's a portion of this that is reflected in the 2024 volume, but also, I would say, technical startup of a new equipment that we have in Pryor and in Wagram, for example. I think in the past we overestimate a little bit the capacity of these equipments or we're more realistic now in the in the targets, but there's still a good potential there.
Okay, thanks. I'll get back in the queue.
Your next question comes from Hamir Patel from CIBC Capital Markets. Please go ahead.
Hi, good morning. Mario, I appreciate all the detail in the strategic plan. I noticed that it referenced CapEx in 2024 for approximately CAD 175 million, but it mentioned that that was before strategic CapEx. You know, in your prepared remarks, you mentioned there's really not much on the table for 2024. Are you able to scale what limited strategic CapEx you would expect to initiate next year? When you do need to move forward with an additional box plant, how should we think about the timing of the spend there? Is that gonna be kind of a 2025 event? What's the sort of scale of investment that might be needed?
Hello, Hamir. As we speak right now, strategic CapEx on the table, we have not, you know. That's why we are focusing our CapEx to CAD 175 million. Nothing is planned, but you know, we always keep our eyes open for opportunity that could be generating good value for the company. For the moment, we have nothing on the table. As for a potential expansion on converting in the Containerboard, in the U.S., if ever we would be moving forward, a facility like this with the new cost of construction and constraint, I would say would be around CAD 85 million-CAD 100 million, depending of how many equipment you would be installing. It will not happen before 2025.
It might take over 18 months.
Absolutely.
A project, we might have a decision for 2025, 2026. But Hamir , everything, all of that will be all linked to our balance sheet and our leverage. We will manage, as Mario mentioned, our priorities in that regard. We might have a decision to move forward in 2024, but it really depends on how we achieve or execute our plan.
Yeah.
The target right now and the focus is really to reduce our debt and, you know, ramp up Bear Island and keep improving the tissue situation.
Okay, great. fair enough. Just the last question I have for Charles. you know, what sort of uplift would you expect in OCC and mixed paper prices as Bear Island ramps up and also some of your competitors' new recycled machines start ramping up as well?
I will let Luc just answer the first part of your question for the OCC. Good morning, Hamir. For the OCC currently, you know, we're living in a global market. As you're probably aware, China is pretty quiet at this moment. It's impacting also the recycled pulp. Brown pulp has been downtime that has been taken in two significant mills in North America now that obviously impact the availability of OCC. The domestic, obviously, is in line with the containerboard production. We're, you know, we're also now in a higher generation season. For the moment, we don't expect significant movement on the OCC pricing for the coming months.
Maybe the other thing also is, location-wise, when we look at the Bear Island, where it's located, and the work that has been done with our sourcing group, we started a year and a half ago to develop some good contact with sources of supply. We're well positioned.
Okay, great. Thanks. That's all I had. I'll turn it over.
Your next question comes from Zachary Evershed from National Bank Financial. Please go ahead.
Thank you. Good morning, everyone.
Morning.
With Bear Island ramping up now, can you tell us a little bit more about your plans for possible inclusion of mixed paper in the furnish and what that could do to your cost of production over time?
Okay. I'm not going to be too detailed, but I can just give you the. When the investment that we made, this mill is very well equipped to have a lot of flexibility. We can go up to a certain rate to 80% of the content for, let's say, if we produce medium, then we can go to up to 80% in mixed waste. I'm not saying that this is what we're going to do, but depending on the market, the dynamic, we can do this. That's why we made the investment on the stock prep and the cleaning capability of the mill. That being said, we can do this in producing very high quality also paper, because this is very important.
We wanna be able to use the mixed waste when the market gets a bit more tighter, but providing to our customers the same level of quality and furnish also on the sheet.
It's important, Zachary, you understand that in the ramp-up mode, we're using better quality material right now to stabilize the machine. As we go, we'll use more mix and, you know, stabilize to, you know, the recipe that Charles just mentioned.
That's great color. Thanks. You haven't mentioned the potential for swing production to kraft paper in a while. Is that still an option that you have available for Bear Island?
I will let Charles answer that question.
Yeah, the machine design again can produce multi-grades. Again, this gives us flexibility and time. At this point, our mix that we are planning to produce is really priority on linerboard and medium to a certain percentage. Really, these are what we're gonna be focusing on.
That's great. Thanks. Just one last one. With the project startup being pushed to the right over time, was there any difficulty in extending the commercial agreements that, the offtake agreements?
No, we've been keeping our customers informed of our ramp-up curve and also the delay, which they understand. On that side, we're well covered. That's why when we provided numbers saying that we're covered on the volume 100% for the first year, you can extend that to the first year of operation, by the way, so the first 12 months and the 75% for the years following. We wanna keep that number, though we have some potential to do better, we're maintaining the same comments based on what we have today.
Makes sense. Thank you. I'll turn it over.
Again, if you'd like to ask a question, please press star one on your telephone keypad. Your next question comes from Michael Roxland from Truist Securities. Please go ahead.
Thank you. You mentioned that you're not seeing the usual seasonal pickup in containerboard volumes. Any way for you to quantify what the usual seasonal pickup is on a percentage basis historically and what you're seeing currently? The reason that I'm asking the question is that a number of your peers have noted that they're seeing a double-digit increase in bookings in April versus March. I wanna just wanna get a sense of what you're seeing relative to what they've already announced.
Our again, as I mentioned, we're being cautious because we did very, very well in what we consider in our Q4 was very, very strong for us. Our Q1 was also good for what we see. We are on the when I say seasonal specialty product or the produce, we usually see higher intake than what we see right now. I would say that our volume right now is about the same as Q1, with some potential being May a bit stronger than April. At this point, again, I wanna be cautious in what we're saying.
Got it. Thank you for the for the color. Would you be able to comment just in terms of think about your integration rate currently as it stands. Can you just remind us how integrated you are roughly? Is it 70% integrated, 75% integrated? If you, if you're more comfortable using a range, just to give a sense of how integrated your overall portfolio is on the Containerboard side.
Okay. We have the number that we have because we have some JV and some numbers that we consider on integration. We're at 76%, including our JV that we or partnership that we own in different businesses.
Got it. That's on the Containerboard side specifically?
Yes.
Okay. Thank you for that. Just one final question real quick. I really appreciate all the color. Can you just remind us, you know, how much of the tonnage from Bear Island will be integrated into your own operations? Is it 50%, 70%? Maybe is it, you know, the way to think about it is maybe it's less today, and as you —because you've delayed your plans to increase your U.S. containerboard converting capacity. Maybe it's at a lower percentage today and you will accelerate that level of integration as you pay down debt and expand your converting capacity. Just help us frame how much you intend to, or how much you're using internally currently and where that should go. Thank you.
As we speak right now, we're using 0 because we're in the ramp- up, we're still improving on the quality of the sheet. We're producing paper, but we need to bring it up to spec before using internally. On our model, what we're planning with the current potential that we have in our converting facility, we wanna go up to about 30% because we still have some capacity in. We're not looking at, on a short term, like Mario explained, to add up some converting. We do have some capacity in our own converting facility, so some potential growth in there.
Our goal is to bring it up to about 30% of the volume to be used internally.
For now.
Yeah. At maturity. Yeah.
Thank you very much.
Thank you. There are no further questions at this time. Mr. Plourde, please continue.
Thank you everyone for being on the call this morning. We appreciate and we're looking forward to present our Q2 result in August. Have a good summer. Thank you.
Merci. Mesdames et Messieurs. Cela met fin à la conférence d'aujourd'hui. Vous pouvez maintenant raccrocher. Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect.